148 related articles for article (PubMed ID: 25420785)
1. Estrogen independent gene expression defines clinically relevant subgroups of estrogen receptor positive breast cancer.
Hallett RM; Hassell JA
BMC Cancer; 2014 Nov; 14():871. PubMed ID: 25420785
[TBL] [Abstract][Full Text] [Related]
2. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
[TBL] [Abstract][Full Text] [Related]
3. Challenges in projecting clustering results across gene expression-profiling datasets.
Lusa L; McShane LM; Reid JF; De Cecco L; Ambrogi F; Biganzoli E; Gariboldi M; Pierotti MA
J Natl Cancer Inst; 2007 Nov; 99(22):1715-23. PubMed ID: 18000217
[TBL] [Abstract][Full Text] [Related]
4. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
5. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
[TBL] [Abstract][Full Text] [Related]
6. A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors.
Yu K; Ganesan K; Miller LD; Tan P
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3288-96. PubMed ID: 16740749
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance.
Karn T; Ruckhäberle E; Hanker L; Müller V; Schmidt M; Solbach C; Gätje R; Gehrmann M; Holtrich U; Kaufmann M; Rody A
Breast Cancer Res Treat; 2011 Nov; 130(2):409-20. PubMed ID: 21203899
[TBL] [Abstract][Full Text] [Related]
9. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns.
Gruvberger S; Ringnér M; Chen Y; Panavally S; Saal LH; Borg A ; Fernö M; Peterson C; Meltzer PS
Cancer Res; 2001 Aug; 61(16):5979-84. PubMed ID: 11507038
[TBL] [Abstract][Full Text] [Related]
12. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype.
Deyarmin B; Kane JL; Valente AL; van Laar R; Gallagher C; Shriver CD; Ellsworth RE
Ann Surg Oncol; 2013 Jan; 20(1):87-93. PubMed ID: 22875649
[TBL] [Abstract][Full Text] [Related]
13. c-Myc overexpression and endocrine resistance in breast cancer.
McNeil CM; Sergio CM; Anderson LR; Inman CK; Eggleton SA; Murphy NC; Millar EK; Crea P; Kench JG; Alles MC; Gardiner-Garden M; Ormandy CJ; Butt AJ; Henshall SM; Musgrove EA; Sutherland RL
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):147-55. PubMed ID: 17052904
[TBL] [Abstract][Full Text] [Related]
14. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
15. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
[TBL] [Abstract][Full Text] [Related]
16. Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt?
Loi S
Eur J Cancer; 2008 Dec; 44(18):2813-8. PubMed ID: 18990560
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
Kadra G; Finetti P; Toiron Y; Viens P; Birnbaum D; Borg JP; Bertucci F; Gonçalves A
Breast Cancer Res Treat; 2012 Apr; 132(3):1035-47. PubMed ID: 21792624
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor.
Levenson AS; Svoboda KM; Pease KM; Kaiser SA; Chen B; Simons LA; Jovanovic BD; Dyck PA; Jordan VC
Cancer Res; 2002 Aug; 62(15):4419-26. PubMed ID: 12154049
[TBL] [Abstract][Full Text] [Related]
19. Comparative expression analysis of four breast cancer subtypes versus matched normal tissue from the same patients.
Martini PG; Taylor DM; Bienkowska J; Jackson J; McAllister G; Keilhack H; Campbell RK
J Steroid Biochem Mol Biol; 2008 Apr; 109(3-5):207-11. PubMed ID: 18424034
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
